Pfizer shares have been trading below both the 50-day and 200-day simple moving averages since mid-June, signaling investor caution about the company's long-term growth outlook. The company expects total revenues for 2026 between $59.5 billion and $62.5 billion, a decline from 2025 revenues of $62.6 billion, driven by lower COVID product sales and a loss of exclusivity cliff that is expected to hurt sales by approximately $1.5 billion in 2026. Adjusted earnings per share are forecast at $2.80 to $3.00 for 2026, down from $3.22 in 2025. Despite these headwinds, Pfizer is rebuilding its pipeline in oncology and obesity, targeting the first potential approvals for its GLP-1 receptor agonist berobenatide in 2028, and expects recently launched and acquired products to drive double-digit growth. The stock currently trades at 8.54 times forward earnings, below the industry average of 18.23 and its five-year mean of 9.37, while offering a dividend yield of around 7%.
Pfizer IncLower COVID product sales and patent cliff hurting revenue and EPS.
Eli Lilly and Company
Novo Nordisk A/S